Dividends & Buybacks ·
VivoSim Labs, Inc. received a notice from Nasdaq on August 17, 2026, indicating it failed to maintain the minimum $1…
VIVSVivoSim Labs, Inc.
VivoSim Labs, Inc. received a notice from Nasdaq on August 17, 2026, indicating it failed to maintain the minimum $1 bid price requirement due to its closing stock price over the preceding 30 consecutive business days. The company has an initial compliance period until February 16, 2027, to regain compliance by achieving a closing price of at least $1 for ten consecutive business days. Failure to comply may result in delisting proceedings, though the company retains the option to seek an additional compliance period if it meets other listing standards. To address this deficiency, VivoSim has included a proposal in its preliminary proxy statement for shareholder approval of a reverse stock split with a ratio between 1-for-5 and 1-for-20, subject to Board determination. The filing does not announce a specific effective date or final ratio for the split. VivoSim Labs operates in the biotechnology sector, focusing on developing simulation technologies for drug discovery.